Analysts have reiterated a Buy rating for Dexcom Inc. with a price target of $84 [1].
This bullish sentiment comes as the San Diego-based company demonstrates strong growth in the continuous glucose monitoring market, suggesting a robust recovery and sustained demand for its medical technology.
Josh Jennings, an analyst at TD Cowen, said in a report this week that he is maintaining the positive outlook [1]. The optimism follows the company's latest financial results, which showed first-quarter sales for the 2026 calendar year rose 15 percent year-over-year to $1.19 billion [2].
Dexcom also reported a non-GAAP profit of $0.56 per share for the first quarter [2]. Despite these figures, the stock experienced some volatility; shares closed last Friday at $69.54 [1].
Looking ahead, the company provided a full-year revenue forecast of approximately $5.21 billion [2]. This projection aligns with analyst estimates and supports the belief that Dexcom maintains a solid market position. The company currently holds a market capitalization of $22.3 billion [3].
Analysts said the strong sales growth and the company's outlook on revenue are the primary drivers for the current valuation targets [1], [2].
“First-quarter sales for the 2026 calendar year rose 15 percent year-over-year to $1.19 billion.”
The alignment between Dexcom's quarterly performance and its full-year guidance suggests a period of predictable growth. While the share price has not yet reached the $84 target, the reiteration of the Buy rating indicates that institutional analysts view the current market price as an undervalued entry point based on the company's dominance in the glucose monitoring sector.
